The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 31-34

  Ridgway, G L ^a,b   Salman, H ^b   Robbins, M J ^b   Dencer, C ^b   Felmingham, D ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b GR Micro Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; DOXYCYCLINE; GREPAFLOXACIN; OFLOXACIN; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; CONTROLLED STUDY; LEGIONELLA; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; UREAPLASMA UREALYTICUM;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHLAMYDIA; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; LEGIONELLA; MYCOPLASMA; OFLOXACIN; PIPERAZINES; QUINOLONES; UREAPLASMA UREALYTICUM;

EID: 0031473725     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.suppl_1.31     Document Type: Conference Paper

References (14)

1. Neu, H. C., Fang, W., Gu. J. W. & Chin, N.-X. (1992). In vitro activity of OPC-17116. Antimicrobial Agents and Chemotherapy 36, 1310-5.
2. Wakebe, H. & Mitsuhashi, S. (1992). Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 36, 2185-91.
3. Spangler, S. K., Jacobs, M. R., Pankuch, G. A. & Appelbaum, P. C. (1993). Susceptibility of 170 penicillin susceptible and penicillin resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Journal of Antimicrobial Chemotherapy 31, 273-80.
4. Wise, R., Andrews, J. M. & Brenwald, N. (1993). The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. Journal of Antimicrobial Chemotherapy 31, 497-504.
5. Zenilman, J. M., Neumann, T., Patton, M. & Reichart, C. (1993). Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy 37, 2244-6.
6. Child, J., Andrews, J. M. & Wise, R. (1995). Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Journal of Antimicrobial Chemotherapy 39, 513-5.
7. Ridgway, G. L., Mumtaz, G., Gabriel, F. G. & Oriel, J. D. (1984). The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and mycoplasmas in vitro. European Journal of Clinical Microbiology 3, 344-6.
8. Fenelon, L E., Mumtaz, G. & Ridgway, G. L. (1990). The invitro antibiotic susceptibility of Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 26, 763-7.
9. Felmingham, D., Robbins, M. J., Sanghrajka, M., Leakey, A. & Ridgway, G. L. (1991). The in vitro activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp., and Ureaplasma urealyticum. Drugs under Experimental and Clinical Research 17, 91-9.
10. Ridgway, G. L. (1995). Quinolones in sexually transmitted diseases. Global experience. Drugs 49, Suppl. 2, 115-22.
11. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. (1994). In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1402-3.
12. Kenny, G. E. & Cartwright, F. D. (1993). Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrobial Agents and Chemotherapy 37, 1726-7.
13. Grüneberg, R. N., Felmingham D., O'Hare, M. D., Robbins, M. J., Perry, K., Wall, R. A. et al. (1988). The comparative in-vitro activity of ofloxacin. Journal of Antimicrobial Chemotherapy 22, Suppl. C, 9-19.
14. Gaja, M. (1992). In vitro and in vivo antibacterial activity of four newly developed quinolone agents against legionella infection. Chemotherapy 40, 1-9.